Eli Lilly
Update in progressLLY (NYSE)
- Company RatingGoodCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. Its portfolio includes diabetes therapies such as Basaglar, Humalog, and several insulin combinations, plus newer agents like Jardiance, Mounjaro, Trulicity, and Zepbound. It also offers oncology drugs (Cyramza, Erbitux, Verzenio, Jaypirca, Retevmo, TYVYT), immunology medicines (Olumiant, Taltz, Ebglyss, Omvoh), Emgality, and Kisubla. Founded 1876, Indianapolis. Collaborations include Boehringer Ingelheim and Roche/Genentech.
Company score
- Sentiment
- 3.26
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 2.65
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.83
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 2.04
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE (NYQ)
- LocationUnited States
- CEOMr. David A. Ricks
- Founded1876
- Employees50,000
- Websitewww.lilly.com
Identifiers
- ISINUS5324571083
- FIGIBBG000BNBDC2
- LEIFRDRIPF3EKNDJ2CQJL29
- CUSIP532457108
- CIK0000059478